US5521184A
(en)
*
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
GB9212673D0
(en)
*
|
1992-06-15 |
1992-07-29 |
Celltech Ltd |
Chemical compounds
|
US6171786B1
(en)
|
1992-09-17 |
2001-01-09 |
Board Of Trustees Of University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
US5972598A
(en)
*
|
1992-09-17 |
1999-10-26 |
Board Of Trustess Of The University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
US5543520A
(en)
*
|
1993-10-01 |
1996-08-06 |
Ciba-Geigy Corporation |
Pyrimidine derivatives
|
WO1995009853A1
(en)
*
|
1993-10-01 |
1995-04-13 |
Ciba-Geigy Ag |
Pharmacologically active pyridine derivatives and processes for the preparation thereof
|
ES2262137T3
(en)
*
|
1993-10-01 |
2006-11-16 |
Novartis Ag |
PHARMACOLOGICALLY ACTIVE PIRIMIDINAMINE DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION.
|
JPH08503971A
(en)
*
|
1993-10-01 |
1996-04-30 |
チバ−ガイギー アクチェンゲゼルシャフト |
Pyrimidineamine derivatives and methods for their preparation
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
JP3806144B2
(en)
*
|
1993-12-22 |
2006-08-09 |
セルテック セラピューティックス リミテッド |
Trisubstituted phenyl derivatives, their preparation and their use as phosphodiesterase (type IV) inhibitors
|
GB9326699D0
(en)
*
|
1993-12-22 |
1994-03-02 |
Celltech Ltd |
Chemical compounds
|
US5786354A
(en)
*
|
1994-06-21 |
1998-07-28 |
Celltech Therapeutics, Limited |
Tri-substituted phenyl derivatives and processes for their preparation
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
GB9412571D0
(en)
*
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412573D0
(en)
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412672D0
(en)
*
|
1994-06-23 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
US5756527A
(en)
*
|
1995-06-07 |
1998-05-26 |
Ontogen Corporation |
Imidazole derivatives useful as modulators of multi drug resistances
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526246D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EP0812829A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Substituted imidazoles as modulators of multi-drug resistance
|
EP0812830A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Modulators of multi-drug resistances
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9622363D0
(en)
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
JP2001507349A
(en)
*
|
1996-12-23 |
2001-06-05 |
セルテック セラピューティックス リミテッド |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
GB9705361D0
(en)
*
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9713087D0
(en)
*
|
1997-06-20 |
1997-08-27 |
Celltech Therapeutics Ltd |
Chemical compounds
|
CO4940418A1
(en)
*
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
|
GB9914258D0
(en)
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
US6498165B1
(en)
|
1999-06-30 |
2002-12-24 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
CA2376957A1
(en)
|
1999-06-30 |
2001-01-04 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
AU5889100A
(en)
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
BR0013899A
(en)
|
1999-09-10 |
2003-07-08 |
Merck & Co Inc |
A compound, pharmaceutical composition, processes for treating or preventing cancer, a disease in which angiogenesis is implicated, retinal vascularization, diabetic retinopathy, age-related macular degeneration, inflammatory diseases, tyrosine-dependent disease or conditions. kinase, bone-associated pathologies, and processes for producing a pharmaceutical composition, and for reducing or preventing tissue damage following a cerebral ischemic event
|
GB9924862D0
(en)
|
1999-10-20 |
1999-12-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
AU2001237041B9
(en)
*
|
2000-02-17 |
2005-07-28 |
Amgen Inc. |
Kinase inhibitors
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7087608B2
(en)
|
2000-03-03 |
2006-08-08 |
Robert Charles Atkins |
Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
JP5073147B2
(en)
|
2000-08-18 |
2012-11-14 |
ミレニアム ファーマシューティカルズ インク. |
Quinazoline derivatives as kinase inhibitors
|
GB0022438D0
(en)
|
2000-09-13 |
2000-11-01 |
Novartis Ag |
Organic Compounds
|
HU229106B1
(en)
*
|
2000-10-27 |
2013-07-29 |
Novartis Ag |
Treatment of gastrointestinal stromal tumors
|
EP1330444B1
(en)
|
2000-11-01 |
2011-03-23 |
Millennium Pharmaceuticals, Inc. |
Nitrogenous heterocyclic compounds and process for making them
|
GB0103926D0
(en)
*
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
EP3143995B2
(en)
|
2001-02-19 |
2025-01-15 |
Novartis Pharma AG |
Rapamycin derivative for the treatment of lung cancer
|
SE0100569D0
(en)
*
|
2001-02-20 |
2001-02-20 |
Astrazeneca Ab |
New compounds
|
MXPA03007729A
(en)
|
2001-02-27 |
2003-12-04 |
Novartis Ag |
Combination comprising a signal transduction inhibitor and an epothilone derivative.
|
CN1700917B
(en)
|
2001-05-16 |
2010-04-28 |
诺瓦提斯公司 |
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
|
EP1395261B1
(en)
*
|
2001-05-16 |
2006-06-28 |
GPC Biotech AG |
Pyridylpyrimidine derivatives as effective compounds against prion diseases
|
US7521175B2
(en)
|
2001-06-14 |
2009-04-21 |
The Regents Of The University Of California |
Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
|
AU2002315388A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel phenylamino-pyrimidines and uses thereof
|
AU2002346053B2
(en)
|
2001-06-22 |
2008-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
CA2452368A1
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
New potent, selective and non toxic c-kit inhibitors
|
EP1401416B1
(en)
|
2001-06-29 |
2006-10-25 |
AB Science |
Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
|
ATE345839T1
(en)
|
2001-06-29 |
2006-12-15 |
Ab Science |
THE USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ALLERGY DISEASES
|
DE60212627T2
(en)
|
2001-06-29 |
2007-06-14 |
Ab Science |
Use of tyrosine kinase inhibitors for the treatment of inflammatory diseases
|
JP2004530730A
(en)
*
|
2001-06-29 |
2004-10-07 |
アブ サイエンス |
Use of a potent, selective and non-toxic c-kit inhibitor for treating tumor angiogenesis
|
JP2005511596A
(en)
*
|
2001-09-20 |
2005-04-28 |
アブ サイエンス |
Methods of using tyrosine kinase inhibitors for whitening human skin and treating diseases associated with melanocyte dysfunction
|
WO2003040141A1
(en)
*
|
2001-09-28 |
2003-05-15 |
Bayer Pharmaceuticals Corporation |
Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
|
EP2343365A1
(en)
|
2001-10-05 |
2011-07-13 |
Novartis AG |
Mutated Abl kinase domains
|
GB0201508D0
(en)
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
GB0202874D0
(en)
*
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
AU2007203462B2
(en)
*
|
2002-02-07 |
2011-01-06 |
Novartis Pharma Ag |
N-phenyl-2-pyrimidine-amine derivatives
|
GB0202873D0
(en)
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
DE60305460D1
(en)
*
|
2002-02-22 |
2006-06-29 |
Us Government |
USE OF 4- (4-METHYLPIPERAZINE-1-YLMETHYL) -N 4-METHYL-3- (4-PYRIDIN-3-YL) PYRIMIDIN-2-YLAMINO) PHENYL BENZAMIDE FOR THE TREATMENT OF SEMINOMES
|
CA2477111A1
(en)
*
|
2002-02-27 |
2003-09-04 |
Ab Science |
Use of tyrosine kinase inhibitors for treating cns disorders
|
ES2314223T3
(en)
*
|
2002-02-27 |
2009-03-16 |
Ab Science |
USE OF THYROSINE KINASE INHIBITORS FOR THE TREATMENT OF DISORDERS FOR USE OF SUBSTANCES.
|
CN1326577C
(en)
*
|
2002-02-28 |
2007-07-18 |
诺瓦提斯公司 |
N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
GB0209265D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
WO2003095448A1
(en)
*
|
2002-05-06 |
2003-11-20 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
AU2003240655B2
(en)
|
2002-05-16 |
2007-09-06 |
Novartis Ag |
Use of EDG receptor binding agents in cancer
|
US7015227B2
(en)
|
2002-06-21 |
2006-03-21 |
Cgi Pharmaceuticals, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
US20060052387A1
(en)
*
|
2002-06-26 |
2006-03-09 |
Marsh Clay B |
Organic compounds
|
ES2337995T3
(en)
*
|
2002-06-28 |
2010-05-03 |
Nippon Shinyaku Co., Ltd. |
DERIVATIVE OF AMIDA.
|
GB0215676D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
MXPA05001277A
(en)
*
|
2002-08-02 |
2005-10-06 |
Ab Science |
2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors.
|
GB0222514D0
(en)
|
2002-09-27 |
2002-11-06 |
Novartis Ag |
Organic compounds
|
AU2003273986A1
(en)
*
|
2002-10-11 |
2004-05-04 |
Novartis Ag |
Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
|
GB0224455D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Novartis Ag |
Organic compounds
|
US7094785B1
(en)
|
2002-12-18 |
2006-08-22 |
Cornell Research Foundation, Inc. |
Method of treating polycythemia vera
|
US7144911B2
(en)
*
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
GB2398565A
(en)
*
|
2003-02-18 |
2004-08-25 |
Cipla Ltd |
Imatinib preparation and salts
|
WO2004087234A1
(en)
*
|
2003-04-04 |
2004-10-14 |
Bayco Tech Limited |
Vascular stent
|
AU2003232650A1
(en)
*
|
2003-05-06 |
2004-11-26 |
Il Yang Pharm Co., Ltd. |
N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
|
EP1628967B1
(en)
|
2003-05-19 |
2014-04-09 |
Irm Llc |
Immunosuppressant compounds and compositions
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
MXPA05012739A
(en)
*
|
2003-05-27 |
2006-05-17 |
Robert Per Hagerkvist |
Use of tyrosine kinase inhibitor to treat diabetes.
|
WO2004110452A1
(en)
*
|
2003-06-13 |
2004-12-23 |
Novartis Ag |
2-aminopyrimidine derivatives as raf kinase inhibitors
|
CN102380098B
(en)
|
2003-08-27 |
2015-07-22 |
奥普索特克公司 |
Combination therapy for the treatment of ocular neovascular disorders
|
BRPI0416680A
(en)
|
2003-11-18 |
2007-02-13 |
Novartis Ag |
mutant form inhibitors
|
LT1702917T
(en)
*
|
2003-12-25 |
2017-12-11 |
Nippon Shinyaku Co., Ltd. |
Amide derivative and medicine
|
EP1725295B1
(en)
|
2004-01-21 |
2010-09-15 |
Emory University |
Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
|
PE20051096A1
(en)
|
2004-02-04 |
2006-01-23 |
Novartis Ag |
SALT FORMS OF 4- (4-METHYLPIPERAZIN-1-ILMETHYL) -N- [4-METHYL-3- (4-PYRIDIN-3-IL) PYRIMIDIN-2-ILAMINO) PHENYL] -BENZAMIDE
|
EP1720853B2
(en)
|
2004-02-11 |
2023-06-28 |
Natco Pharma Limited |
Pharmaceutical compositions of the 2 crystalline form of imatinib mesylate for use in the treatment of chronic myelogenous leukemia
|
CN1309719C
(en)
*
|
2004-02-18 |
2007-04-11 |
陈国庆 |
Derivative of phenylamide pyrimidine and application thereof
|
EP1735307B1
(en)
|
2004-04-07 |
2012-08-29 |
Novartis AG |
Inhibitors of iap
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
US20080187575A1
(en)
*
|
2004-08-27 |
2008-08-07 |
Bert Klebl |
Pyrimidine Derivatives
|
WO2006024863A1
(en)
|
2004-09-02 |
2006-03-09 |
Cipla Limited |
Stable crystal form of imatinib mesylate and process for the preparation thereof
|
US8735415B2
(en)
|
2004-09-09 |
2014-05-27 |
Natco Pharma Limited |
Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
US7939541B2
(en)
*
|
2004-09-09 |
2011-05-10 |
Natco Pharma Limited |
Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
KR100948453B1
(en)
|
2004-09-09 |
2010-03-17 |
낫코 파마 리미티드 |
Novel Phenylaminopyrimidine Derivatives as WRC-ALLL Kinase Inhibitors
|
WO2006054314A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Natco Pharma Limited |
Polymorphic forms of imatinib mesylate
|
DE602005023658D1
(en)
*
|
2004-12-30 |
2010-10-28 |
Inst Farmaceutyczny |
PROCESS FOR THE PRODUCTION OF IMATINIB BASE
|
CN1972917B
(en)
*
|
2004-12-31 |
2010-08-25 |
孙飘扬 |
Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
|
CN1939910A
(en)
*
|
2004-12-31 |
2007-04-04 |
孙飘扬 |
Amino-metadiazine compound and its salt, its preparation and pharmaceutical use
|
WO2006077424A1
(en)
|
2005-01-21 |
2006-07-27 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
CA2606716C
(en)
|
2005-05-02 |
2013-07-23 |
Novartis Ag |
Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
UA96139C2
(en)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Anti-neuropilin-1 (nrp1) antibody
|
EP2275103B1
(en)
|
2005-11-21 |
2014-04-23 |
Novartis AG |
mTOR inhibitors in the treatment of endocrine tumors
|
CN102351842B
(en)
|
2005-11-25 |
2014-07-23 |
诺华股份有限公司 |
F,G,H,I and K crystal forms of imatinib mesylate
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
RU2452492C2
(en)
|
2006-04-05 |
2012-06-10 |
Новартис Аг |
COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER
|
KR20080108517A
(en)
|
2006-04-05 |
2008-12-15 |
노파르티스 아게 |
Combination of Therapeutics to Treat Cancer
|
PE20110235A1
(en)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
|
CN101443002B
(en)
|
2006-05-09 |
2012-03-21 |
诺瓦提斯公司 |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
US20060223817A1
(en)
*
|
2006-05-15 |
2006-10-05 |
Chemagis Ltd. |
Crystalline imatinib base and production process therefor
|
WO2007138705A1
(en)
|
2006-06-01 |
2007-12-06 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
Tumor suppressor
|
BRPI0717564A2
(en)
|
2006-09-29 |
2013-10-22 |
Novartis Ag |
PIRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP5528807B2
(en)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
Compound drug
|
JP2009514988A
(en)
*
|
2006-10-26 |
2009-04-09 |
シコール インコーポレイティド |
Imatinib base and imatinib mesylate and methods for their preparation
|
WO2008059551A2
(en)
|
2006-11-16 |
2008-05-22 |
F.I.S. Fabbrica Italiana Sintetici S.P.A. |
Process for the preparation of imatinib and intermediates thereof
|
CN101245061B
(en)
*
|
2007-02-13 |
2012-09-19 |
天津天士力集团有限公司 |
N-(5-amido-2-methyl phenyl)-4-(3-pyridinyl)-2-aminopyrimidine nitric oxide donating derivant, production method and uses thereof
|
EP2120900A2
(en)
|
2007-02-15 |
2009-11-25 |
Novartis AG |
Combination of lbh589 with other therapeutic agents for treating cancer
|
RU2329260C1
(en)
*
|
2007-02-20 |
2008-07-20 |
Юрий Иосифович Копырин |
Method of obtaining 2-anilinopyrimidines or their salts (options)
|
MX2009009659A
(en)
*
|
2007-03-12 |
2009-09-22 |
Reddys Lab Ltd Dr |
Imatinib mesylate.
|
WO2008117298A1
(en)
*
|
2007-03-26 |
2008-10-02 |
Natco Pharma Limited |
A novel method of preparation of imatinib
|
US7550591B2
(en)
|
2007-05-02 |
2009-06-23 |
Chemagis Ltd. |
Imatinib production process
|
WO2008136010A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Natco Pharma Limited |
A process for the preparation of highly pure imatinib base
|
US8367686B2
(en)
|
2007-06-07 |
2013-02-05 |
Intra-Cellular Therapies, Inc. |
Heterocycle compounds and uses thereof
|
EP2166860B1
(en)
|
2007-06-07 |
2016-09-21 |
Intra-Cellular Therapies, Inc. |
Novel heterocycle compounds and uses thereof
|
JP5611826B2
(en)
*
|
2007-09-04 |
2014-10-22 |
ザ スクリプス リサーチ インスティテュート |
Substituted pyrimidinyl-amines as protein kinase inhibitors
|
WO2009060463A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Natco Pharma Limited |
An environmentally friendly process for the preparation of imatinib base
|
EP2062885A1
(en)
*
|
2007-11-21 |
2009-05-27 |
Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. |
Acid addition salts of imatinib and formulations comprising the same
|
RU2493152C2
(en)
*
|
2008-02-01 |
2013-09-20 |
Акинион Фармасьютикалз Аб |
Novel compounds, use and production thereof
|
BRPI0908603A2
(en)
|
2008-03-24 |
2020-08-18 |
Novartis Ag |
matrix metalloprotease inhibitors based on arylsulfonamide.
|
JP5330498B2
(en)
|
2008-03-26 |
2013-10-30 |
ノバルティス アーゲー |
Hydroxamate-based inhibitors of deacetylase B
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
CN101584696A
(en)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
Composition containing quinazoline derivatives, preparation method and use
|
KR101860057B1
(en)
|
2008-05-21 |
2018-05-21 |
어리어드 파마슈티칼스, 인코포레이티드 |
Phosphorous derivatives as kinase inhibitors
|
PL215042B1
(en)
*
|
2008-08-01 |
2013-10-31 |
Temapharm Spolka Z Ograniczona Odpowiedzialnoscia |
Method of imatinib manufacturing
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
AU2009281122C1
(en)
|
2008-08-15 |
2016-04-21 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
EA023148B1
(en)
|
2008-08-25 |
2016-04-29 |
Эмплиммьюн, Инк. |
Compositions of pd-1 antagonists and use thereof
|
ES2704986T3
(en)
|
2008-10-16 |
2019-03-21 |
Celator Pharmaceuticals Inc |
Combinations of a water-soluble liposomal camptothecin with cetuximab or bevacizumab
|
EP2186514B1
(en)
|
2008-11-14 |
2016-06-29 |
Kinki University |
Treatment of Malignant Peripheral Nerve Sheath Tumors
|
CN103204794A
(en)
|
2008-12-18 |
2013-07-17 |
诺瓦提斯公司 |
New Salts
|
UY32330A
(en)
|
2008-12-18 |
2010-07-30 |
Novartis Ag |
NEW FORM OF SALT OF ACID 1- (4- {1- [E-4-CICLOHEXIL-3-TRIFLUORO-METIL-BENCILOXI-IMINO] -ETIL} -2-ETIL-BENCIL) -AZETIDIN-3-CARBOXYLICAL, POLYMODIC FORMS , PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
|
WO2010071794A1
(en)
|
2008-12-18 |
2010-06-24 |
Novartis Ag |
New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
|
BRPI0923121A2
(en)
|
2008-12-23 |
2015-08-11 |
Boehringer Ingelheim Int |
Saline forms of organic compounds
|
AR074990A1
(en)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
TWI466672B
(en)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
Treatment for diabetes in paediatric patients
|
JP2012516345A
(en)
|
2009-01-29 |
2012-07-19 |
ノバルティス アーゲー |
Substituted benzimidazoles for astrocytoma treatment
|
EA029759B1
(en)
|
2009-02-13 |
2018-05-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Antidiabetic medications comprising dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetic agents
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
JP2012519282A
(en)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Methods for identifying mesenchymal tumor cells or agents that inhibit their production
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519281A
(en)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Methods for identifying mesenchymal tumor cells or agents that inhibit their production
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
TW201102068A
(en)
|
2009-06-02 |
2011-01-16 |
Novartis Ag |
Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
|
EA021011B1
(en)
|
2009-06-26 |
2015-03-31 |
Новартис Аг |
1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF Cyp 17
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(en)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
|
SG10201404886PA
(en)
|
2009-08-17 |
2014-10-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
EP2467383A1
(en)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclic oxime compounds
|
WO2011023677A1
(en)
|
2009-08-26 |
2011-03-03 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
EA201200471A1
(en)
|
2009-09-10 |
2012-10-30 |
Новартис Аг |
SIMPLE ESSENTIAL DERIVATIVES OF BICYCLIC HETEROARILS
|
NZ598170A
(en)
|
2009-10-02 |
2014-06-27 |
Boehringer Ingelheim Int |
Pharmaceutical compositions comprising bi-1356 and metformin
|
CN102686579A
(en)
|
2009-10-09 |
2012-09-19 |
Irm责任有限公司 |
Compounds and compositions as modulators of GPR119 activity
|
PL389357A1
(en)
|
2009-10-22 |
2011-04-26 |
Tomasz Koźluk |
Tartaric acids derivatives imatinib salts and process for the preparation thereof
|
EP2496575B1
(en)
|
2009-11-04 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
EA201200617A1
(en)
|
2009-11-23 |
2012-11-30 |
Серулин Фарма Инк. |
POLYMERS ON THE BASIS OF CYCLODEXTRINE FOR DELIVERY OF MEDICINES
|
WO2011064211A1
(en)
|
2009-11-25 |
2011-06-03 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
JP2013512229A
(en)
|
2009-11-27 |
2013-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Treatment of diabetic patients whose genotype has been identified with DDP-IV inhibitors such as linagliptin
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
JP5456908B2
(en)
|
2009-12-08 |
2014-04-02 |
ノバルティス アーゲー |
Heterocyclic sulfonamide derivatives
|
WO2012168884A1
(en)
|
2011-06-09 |
2012-12-13 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
EP2509973A1
(en)
|
2009-12-10 |
2012-10-17 |
Arch Pharmalabs Limited |
Process for the preparation of imatinib and salts thereof
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(en)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011099039A1
(en)
|
2010-02-15 |
2011-08-18 |
Reliance Life Sciences Pvt. Ltd. |
Process for the preparation of alpha form of imatinib mesylate
|
PL390611A1
(en)
|
2010-03-04 |
2011-09-12 |
Tomasz Koźluk |
Process for the preparation of polymorphic alpha form and new polymorphic form of imatinib mesylate
|
CA2792472A1
(en)
|
2010-03-15 |
2011-09-22 |
Natco Pharma Limited |
Process for the preparation of highly pure crystalline imatinib base
|
EP2547339A1
(en)
|
2010-03-18 |
2013-01-23 |
Boehringer Ingelheim International GmbH |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
US8609842B2
(en)
*
|
2010-04-23 |
2013-12-17 |
Fujian South Pharmaceutical Co., Ltd. |
Method for synthesizing Imatinib
|
EP2382976A1
(en)
|
2010-04-30 |
2011-11-02 |
Hiroshima University |
Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
|
AU2011249722B2
(en)
|
2010-05-05 |
2015-09-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
JP2013532149A
(en)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
Piperidinyl-substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
|
WO2011157787A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
EA024088B1
(en)
|
2010-06-18 |
2016-08-31 |
КРКА, д.д., НОВО МЕСТО |
Alpha-form of imatinib mesylate, processes for preparation thereof and pharmaceutical composition comprising the same
|
WO2011160798A1
(en)
|
2010-06-21 |
2011-12-29 |
Zaklady Farmaceutyczne Polpharma Sa |
Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
|
BR112012032579B1
(en)
|
2010-06-24 |
2021-05-11 |
Boehringer Ingelheim International Gmbh |
use of linagliptin and pharmaceutical composition comprising linagliptin and long-acting basal insulin
|
UA112517C2
(en)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
|
EP2591004A1
(en)
|
2010-07-09 |
2013-05-15 |
F.Hoffmann-La Roche Ag |
Anti-neuropilin antibodies and methods of use
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
WO2012019633A1
(en)
|
2010-08-11 |
2012-02-16 |
Synthon B.V. |
Pharmaceutical granulate comprising imatinib mesylate
|
TR201007005A2
(en)
|
2010-08-23 |
2011-09-21 |
Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. |
Imatinib base production method
|
CN103108871B
(en)
|
2010-09-16 |
2014-09-10 |
诺华股份有限公司 |
17a-hydroxylase/c17,20-lyase inhibitors
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TR201010618A2
(en)
|
2010-12-20 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
An oral dosage form comprising imatinib and the manufacture of an oral dosage form
|
AU2011346567A1
(en)
|
2010-12-21 |
2013-07-25 |
Novartis Ag |
Bi-heteroaryl compounds as Vps34 inhibitors
|
WO2012090221A1
(en)
|
2010-12-29 |
2012-07-05 |
Cadila Healthcare Limited |
Novel salts of imatinib
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
TWI592411B
(en)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
Combination of kinase inhibitors and uses thereof
|
JP5808826B2
(en)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
Heterocyclic compounds and uses thereof
|
CZ305457B6
(en)
|
2011-02-28 |
2015-09-30 |
Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. |
Pyrimidine compounds inhibiting formation of nitrogen monoxide and prostaglandin E2, process for their preparation and use
|
EP2683722A1
(en)
|
2011-03-08 |
2014-01-15 |
Novartis AG |
Fluorophenyl bicyclic heteroaryl compounds
|
PL394169A1
(en)
|
2011-03-09 |
2012-09-10 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
The pharmaceutical composition of imatinib mesylate for filling unit dosage forms and the method for its preparation
|
EP2508525A1
(en)
|
2011-04-05 |
2012-10-10 |
Bayer Pharma Aktiengesellschaft |
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
WO2012149413A1
(en)
|
2011-04-28 |
2012-11-01 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
EA201391626A1
(en)
|
2011-05-04 |
2014-03-31 |
Ариад Фармасьютикалз, Инк. |
COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-STIMULATED CANCER TYPES
|
CN102796110B
(en)
*
|
2011-05-23 |
2016-03-30 |
复旦大学 |
Aniline pyrimidine compound and its production and use
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
US9750700B2
(en)
|
2011-06-22 |
2017-09-05 |
Natco Pharma Limited |
Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
|
SG195067A1
(en)
|
2011-06-27 |
2013-12-30 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
ITMI20111309A1
(en)
|
2011-07-14 |
2013-01-15 |
Italiana Sint Spa |
PREPARATION PROCEDURE OF IMATINIB MESILATO
|
US8962636B2
(en)
|
2011-07-15 |
2015-02-24 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
WO2013035102A1
(en)
|
2011-09-05 |
2013-03-14 |
Natco Pharma Limited |
Processes for the preparation of imatinib base and intermediates thereof
|
BR112014006223A8
(en)
|
2011-09-15 |
2018-01-09 |
Novartis Ag |
6-substituted 3- (quinolin-6-ylthio) - [1,2,4-triazol [4,3-a] pyradines, their uses, pharmaceutical compositions, and combination
|
CA2853961C
(en)
|
2011-11-01 |
2016-09-20 |
Modgene, Llc |
Compositions and methods for reduction of amyloid-beta load
|
RU2486180C1
(en)
*
|
2011-11-02 |
2013-06-27 |
Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") |
Method for preparing 2-arylamino-4-hetarylpyrimidines
|
EP2785717B1
(en)
|
2011-11-29 |
2016-01-13 |
Novartis AG |
Pyrazolopyrrolidine compounds
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
CN103159739A
(en)
*
|
2011-12-09 |
2013-06-19 |
天津市国际生物医药联合研究院有限公司 |
1, 4-disubstituted-1, 2, 3-triazole compounds and preparation method thereof
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
DK2794600T3
(en)
|
2011-12-22 |
2018-03-12 |
Novartis Ag |
-2,3-Dihydro-benzo [1,4] oxazine derivatives and related compounds such as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of rheumatoid arthritis
|
KR20140107575A
(en)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
EP2794589A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
JP2015503515A
(en)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
COMPOUND AND COMPOSITION FOR INHIBITING BCL2 AND BINDING PARTY INTERACTION
|
EA201491264A1
(en)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL-2 WITH PARTNERS ON BINDING
|
BR112014015339A2
(en)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compounds for inhibiting bcl2 interaction with binding partners
|
US20130172244A1
(en)
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
PL226174B1
(en)
|
2011-12-30 |
2017-06-30 |
Inst Farm |
Combination therapy of non-small-cell lung carcinoma
|
JO3357B1
(en)
|
2012-01-26 |
2019-03-13 |
Novartis Ag |
Imidazopyrrolidinone compounds
|
GB2514285B
(en)
|
2012-02-13 |
2018-07-18 |
Grindeks Jsc |
Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
|
WO2013136141A1
(en)
|
2012-03-13 |
2013-09-19 |
Fresenius Kabi Oncology Ltd. |
An improved process for the preparation of alpha form of imatinib mesylate
|
CN104245701A
(en)
|
2012-04-03 |
2014-12-24 |
诺华有限公司 |
Combination with tyrosine kinase inhibitors and use thereof
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN104379560A
(en)
|
2012-04-24 |
2015-02-25 |
中外制药株式会社 |
Benzamide derivative
|
BR112014026305A2
(en)
|
2012-04-24 |
2017-06-27 |
Chugai Pharmaceutical Co Ltd |
quinazolidinedione derivative
|
JP6469567B2
(en)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Compound for inhibiting cell proliferation of EGFR-activated cancer
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013171166A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2013174768A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
|
JP6171003B2
(en)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
Pyrrolopyrrolidinone compounds
|
BR112014031421A2
(en)
|
2012-06-15 |
2017-06-27 |
Brigham & Womens Hospital Inc |
cancer treatment compositions and methods for producing them
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
WO2014025395A1
(en)
|
2012-08-06 |
2014-02-13 |
Duke University |
Compounds and methods for targeting hsp90
|
WO2014041551A1
(en)
|
2012-09-14 |
2014-03-20 |
Natco Pharma Limited |
Formulation comprising imatinib as oral solution
|
CN103664787B
(en)
|
2012-09-17 |
2015-09-09 |
南京圣和药业股份有限公司 |
Alkynes heteroaromatic ring compounds and application thereof
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
WO2014048377A1
(en)
|
2012-09-28 |
2014-04-03 |
杭州本生药业有限公司 |
Drug composition for treating tumors and application thereof
|
EP2903979B1
(en)
*
|
2012-10-04 |
2020-08-19 |
Inhibikase Therapeutics, Inc. |
Novel compounds, their preparation and their uses
|
AU2013337247B2
(en)
|
2012-11-05 |
2018-08-09 |
Dana-Farber Cancer Institute, Inc. |
XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
|
TW201422625A
(en)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
Solid form of dihydro-pyrido-oxazine derivative
|
CN103848812B
(en)
*
|
2012-12-04 |
2016-08-03 |
北大方正集团有限公司 |
The method of refined imatinib
|
CN103044394A
(en)
*
|
2012-12-20 |
2013-04-17 |
北京理工大学 |
Phenyl aminopyrimidine derivant and preparation method and application thereof
|
EP2749271A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Optimized manufacturing method and pharmaceutical formulation of imatinib
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
WO2014124860A1
(en)
|
2013-02-14 |
2014-08-21 |
Boehringer Ingelheim International Gmbh |
Specific pde4b-inhibitors for the treatment of diabetes mellitus
|
KR102509562B1
(en)
|
2013-02-20 |
2023-03-14 |
노파르티스 아게 |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
CN105246482A
(en)
|
2013-03-15 |
2016-01-13 |
因特利凯有限责任公司 |
Combinations of kinase inhibitors and uses thereof
|
EP3409279A1
(en)
|
2013-03-15 |
2018-12-05 |
Boehringer Ingelheim International GmbH |
Use of linagliptin in cardio- and renoprotective antidiabetic therapy
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
ES2683361T3
(en)
|
2013-05-14 |
2018-09-26 |
Hetero Research Foundation |
Imatinib compositions
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(en)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
AU2014321419B2
(en)
|
2013-09-22 |
2017-06-15 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2015055898A2
(en)
|
2013-10-17 |
2015-04-23 |
Sihto Harri |
Compositions comprising phosphodiesterase inhibitors for use in the treatment of a solid tumor in a human patient
|
TW201605805A
(en)
|
2013-10-23 |
2016-02-16 |
Chugai Pharmaceutical Co Ltd |
Quinazolinone and isoquinolinone derivative
|
TW201605450A
(en)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Combination of Mdm2 inhibitor and BRAF inhibitor and their use
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
EP3122730B1
(en)
|
2014-03-28 |
2020-03-25 |
Calitor Sciences, LLC |
Substituted heteroaryl compounds and methods of use
|
JP2017513931A
(en)
|
2014-04-03 |
2017-06-01 |
インビクタス オンコロジー ピーヴィティー.リミテッド |
Supramolecular combinatorial treatment
|
US9630944B2
(en)
|
2014-04-04 |
2017-04-25 |
F.I.S.—Fabbrica Italiana Sintetici S.p.A. |
Process for preparing Imatinib and salts thereof, free of genotoxic impurity F
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
CA2954862A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Combination therapy
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
CN105585556A
(en)
*
|
2014-11-13 |
2016-05-18 |
连云港杰瑞药业有限公司 |
Synthetic method of imatinib
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
WO2017129624A1
(en)
|
2016-01-25 |
2017-08-03 |
Krka, D.D., Novo Mesto |
Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
|
KR102293847B1
(en)
|
2016-03-25 |
2021-08-26 |
에이비 사이언스 |
Use of masitinib for the treatment of a subpopulation of patients with amyotrophic lateral sclerosis
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
US10155000B2
(en)
|
2016-06-10 |
2018-12-18 |
Boehringer Ingelheim International Gmbh |
Medical use of pharmaceutical combination or composition
|
EP3257499A1
(en)
|
2016-06-17 |
2017-12-20 |
Vipharm S.A. |
Process for preparation of imatinib methanesulfonate capsules
|
CN107652269A
(en)
*
|
2016-07-26 |
2018-02-02 |
江苏豪森药业集团有限公司 |
Methanesulfonic acid fluorine imatinib purification of intermediate method
|
WO2018039205A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
CN107805240A
(en)
*
|
2016-09-08 |
2018-03-16 |
中国科学院合肥物质科学研究院 |
A kind of new PDGFR kinase inhibitors and application thereof
|
MX389789B
(en)
|
2016-09-27 |
2025-03-20 |
Cero Therapeutics Inc |
CHIMERICAL ENVELOPEMENT RECEPTOR MOLECULES.
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
EP3333162A1
(en)
|
2016-12-12 |
2018-06-13 |
Silesian Catalysts sp. z o.o. |
Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
|
CN107089969B
(en)
*
|
2017-04-26 |
2020-04-24 |
黑龙江鑫创生物科技开发有限公司 |
Method for synthesizing imatinib intermediate
|
WO2019067328A1
(en)
|
2017-09-26 |
2019-04-04 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules and methods of use
|
CA3079422A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and hdac inhibitors for treating multiple myeloma
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3730483B1
(en)
|
2017-12-21 |
2023-08-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
JP7450541B2
(en)
|
2018-01-20 |
2024-03-15 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
Substituted aminopyrimidine compounds and methods of use
|
RU2020135107A
(en)
|
2018-03-28 |
2022-04-29 |
Серо Терапьютикс, Инк. |
CELLULAR IMMUNOTHERAPEUTIC COMPOSITIONS AND THEIR APPLICATIONS
|
US12291557B2
(en)
|
2018-03-28 |
2025-05-06 |
Cero Therapeutics Holdings, Inc. |
Chimeric TIM4 receptors and uses thereof
|
US20210024607A1
(en)
|
2018-03-28 |
2021-01-28 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
BR112020026164A2
(en)
|
2018-07-17 |
2021-03-23 |
Boehringer Ingelheim International Gmbh |
cardioprotective and nephroprotective antidiabetic therapy
|
KR20210032468A
(en)
|
2018-07-17 |
2021-03-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
Heart-safe antidiabetic therapy
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
WO2021009686A1
(en)
|
2019-07-15 |
2021-01-21 |
Intas Pharmaceuticals Ltd. |
Pharmaceutical composition of imatinib
|
EP4038097A1
(en)
|
2019-10-03 |
2022-08-10 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
US12359208B2
(en)
|
2020-04-15 |
2025-07-15 |
California Institute Of Technology |
Thermal control of T-cell immunotherapy through molecular and physical actuation
|
WO2021228983A1
(en)
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
|
WO2022029220A1
(en)
|
2020-08-05 |
2022-02-10 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022047259A1
(en)
|
2020-08-28 |
2022-03-03 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
TW202237638A
(en)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
|
WO2022183072A1
(en)
|
2021-02-26 |
2022-09-01 |
Kelonia Therapeutics, Inc. |
Lymphocyte targeted lentiviral vectors
|
JP2024529474A
(en)
|
2021-07-28 |
2024-08-06 |
セロ・セラピューティクス・インコーポレイテッド |
Chimeric Tim4 receptor and uses thereof
|
IL318710A
(en)
|
2022-08-02 |
2025-03-01 |
Univ Hokkaido Nat Univ Corp |
Methods of improving cellular therapy with organelle complexes
|